Boehringer Ingelheim India signs MoUs with NIPER Ahmedabad and Hyderabad to expand research collaboration

This collaboration across the NIPER network- Raebareli, Hajipur, Ahmedabad and Hyderabad is strengthening translational research and opnMe access

Boehringer Ingelheim India has signed two separate five-year Memoranda of Understanding (MoUs) with the National Institutes of Pharmaceutical Education and Research (NIPER) branches in Ahmedabad and Hyderabad. Formalised at a joint ceremony in Hyderabad, these strategic agreements establish a collaborative framework aimed at advancing pharmaceutical research, academic exchange, and talent capability-building.

The MoU signing ceremony was attended by leadership from both institutes, including Dr. Shailendra Saraf, Director, NIPER-Ahmedabad and Hyderabad; Dr. Srinivas Nanduri, Professor & Dean, NIPER Hyderabad;, Dr. Jitender Madan, Professor, NIPER Hyderabad; Dr. Akshay Srivastava, Professor & Dean, NIPER Ahmedabad and Dr. Rajesh Kumar, Assistant Professor, NIPER Hyderabad. Under this agreement, Boehringer Ingelheim India will grant faculty and researchers at both campuses access to its global open science portal, opnMe.

Through opnMe, the same molecules used by top global scientists for early-stage biological research are now directly accessible to researchers in Gandhinagar. This transition perfectly reflects a broader shift: India's pharmaceutical industry is evolving from pure manufacturing to global scientific discovery. Positioned right at the heart of this transformation, the Biopharma SHAKTI initiative has placed biologics at the center of the nation's next pharmaceutical chapter, heavily supported by key partnerships like the one with NIPER, Hyderabad.

These two MoUs build on the partnerships signed earlier in 2026 with the institutes at Raebareli and Hajipur. With these new agreements, Boehringer Ingelheim India’s open science collaboration now extends across northern, eastern, western and southern India.

Dr. Shailendra Saraf, Director, NIPER - Ahmedabad and Hyderabad, “India’s transition from a generics-led to an innovation-led pharmaceutical economy will not be made by any single institution or any single company. It will be made by the academia-industry network we are building across the country. Two Memoranda signed on one day, with two of our most important National Institutes of Pharmaceutical Education and Research, is the pace at which Biopharma SHAKTI is meant to operate, and the pace the sector now expects of itself.”

Meenal Gauri, Managing Director, Boehringer Ingelheim India, ‘opnMe’ began as a way for Boehringer Ingelheim scientists to share what they had built with the global research community. In India, it is becoming something more, a structured network of partnerships with the institutions that will shape the country’s pharmaceutical talent for the next decade. After Raebareli and Hajipur, signing with Ahmedabad and Hyderabad is a significant commitment, and we see this as the deepening of a long-term commitment to India’s pharmaceutical education network.”

The collaborations are structured on a non-profit, non-commercial basis, reflecting the shared commitment of Boehringer Ingelheim India and the National Institutes of Pharmaceutical Education and Research to ethical research, pharmaceutical education and the public good.